Cash Dividend On The Way From Kewaunee Scientific (KEQU)

Looking at the universe of stocks we cover at Dividend Channel, on 9/4/14, Kewaunee Scientific Corporation (KEQU) will trade ex-dividend, for its quarterly dividend of $0.12, payable on 9/22/14. As a percentage of KEQU's recent stock price of $18.02, this dividend works out to approximately 0.67%, so look for shares of Kewaunee Scientific Corporation to trade 0.67% lower — all else being equal — when KEQU shares open for trading on 9/4/14.

START SLIDESHOW:
Click here to learn which 25 S.A.F.E. dividend stocks should be on your radar screen »

Below is a dividend history chart for KEQU, showing historical dividends prior to the most recent $0.12 declared by Kewaunee Scientific Corporation:

KEQU+Dividend+History+Chart

In general, dividends are not always predictable; but looking at the history above can help in judging whether the most recent dividend from KEQU is likely to continue, and whether the current estimated yield of 2.66% on annualized basis is a reasonable expectation of annual yield going forward.The chart below shows the one year performance of KEQU shares, versus its 200 day moving average:

Kewaunee Scientific Corporation 200 Day Moving Average Chart

Looking at the chart above, KEQU's low point in its 52 week range is $14.81 per share, with $18.75 as the 52 week high point — that compares with a last trade of $17.99.

In Tuesday trading, Kewaunee Scientific Corporation shares are currently trading flat on the day.

More from Stocks

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

3 Great Stock Market Sectors Millennials Should Invest In

3 Great Stock Market Sectors Millennials Should Invest In

Why Millennials Are Ditching Stocks for ETFs

Why Millennials Are Ditching Stocks for ETFs

Trump's 'Space Force' Could Launch a $1 Trillion Industry, Morgan Stanley Says

Trump's 'Space Force' Could Launch a $1 Trillion Industry, Morgan Stanley Says

Abiomed Stock Should Rise Some 12% From Here, Piper Jaffray Analyst Says

Abiomed Stock Should Rise Some 12% From Here, Piper Jaffray Analyst Says